Bollen Wendy S, Gunn Bronwyn M, Mo Hua, Lay Margarita K, Curtiss Roy
Department of Biology, Washington University, St. Louis, Missouri 63130-4899, USA.
Infect Immun. 2008 Jul;76(7):3268-72. doi: 10.1128/IAI.00244-08. Epub 2008 May 12.
Salmonella enterica serovar Typhi and Typhimurium vaccine candidates elicit significant immune responses in mice by intranasal (i.n.) immunization. Because of the proximity of the cribriform plate of the ethmoid bone, we were concerned that Salmonella bacteria delivered i.n. might access the brain. Accordingly, wild-type and attenuated (by single and double mutations) strains of S. enterica serovars Typhimurium and Typhi were recovered at low numbers initially from the olfactory lobe and then from the brain for 3 to 4 days after i.n. immunization. This was independent of invA gene function. Although the presence of bacteria in blood 1 to 3 h after i.n. inoculation was sometimes observed, this was infrequent compared to the frequency of bacteria detected in brain tissues. In confirmation of recent observations by Wickham et al. (M. E. Wickham, N. F. Brown, J. Provias, B. B. Finlay, and B. K. Coombes, BMC Infect. Dis. 7:65, 2007) that oral inoculation with wild-type S. enterica serovar Typhimurium strains lead to bacteria in blood with subsequent colonization of brain tissues with neurological symptoms of disease, we found similar results by using the i.n. and intraperitoneal (i.p.) routes of inoculation for wild-type but not for attenuated strains of S. enterica serovar Typhimurium. In contrast, a highly modified attenuated S. enterica serovar Typhimurium strain was not present in brain tissues when administered at higher doses by the oral, i.n., and i.p. routes than the wild-type strain even though the presence of bacteria in blood was detectable 1 to 3 h after inoculation by each of the three routes. Our results indicate that i.n. and possibly even oral delivery of live Salmonella vaccines may be unsafe although it is possible to reduce this risk by appropriate genetic modifications.
肠炎沙门氏菌伤寒血清型和鼠伤寒血清型候选疫苗通过鼻内免疫在小鼠中引发显著的免疫反应。由于筛骨筛板位置临近,我们担心经鼻内接种的沙门氏菌可能进入大脑。因此,在鼻内免疫后3至4天,最初在嗅叶中少量回收了鼠伤寒和伤寒血清型肠炎沙门氏菌的野生型和减毒株(通过单突变和双突变),随后在大脑中也有回收。这与invA基因功能无关。尽管有时在鼻内接种后1至3小时血液中会检测到细菌,但与脑组织中检测到细菌的频率相比,这种情况并不常见。正如威克姆等人最近的观察结果所证实的那样(M. E. 威克姆、N. F. 布朗、J. 普罗维亚斯、B. B. 芬利和B. K. 库姆斯,《BMC传染病》7:65,2007),口服野生型肠炎沙门氏菌鼠伤寒血清型菌株会导致血液中出现细菌,随后细菌在脑组织中定植并出现疾病的神经症状,我们通过鼻内和腹腔内接种途径对野生型但非减毒的肠炎沙门氏菌鼠伤寒血清型菌株进行接种也得到了类似结果。相比之下,一种经过高度修饰的减毒肠炎沙门氏菌鼠伤寒血清型菌株,当通过口服、鼻内和腹腔内途径给予比野生型菌株更高的剂量时,脑组织中未检测到该菌株,尽管通过这三种途径接种后1至3小时血液中均可检测到细菌。我们的结果表明,鼻内甚至可能口服活沙门氏菌疫苗可能不安全,尽管通过适当的基因改造有可能降低这种风险。